Every Retatrutide Research Question Answered, in 27 Studies

27 referenced articles

• Does Retatrutide Affect Testosterone?2 sources
• Retatrutide: What the Trials Show For and Against2 sources
• Retatrutide Side Effects Reported So Far2 sources
• Is Retatrutide Legal?3 sources
• Fake Retatrutide and What a Certificate Can Prove2 sources
• Is There a Retatrutide Tablet or Pill?3 sources
• Retatrutide and Alcohol3 sources
• Retatrutide vs Mounjaro, Ozempic and Wegovy4 sources
• What "Reta" on a Label Actually Tells You3 sources
• What Is Retatrutide? LY3437943, and What a Triple Agonist Does4 sources
• How One Peptide Engages Three Receptors3 sources
• Retatrutide in the Published Literature4 sources
• Retatrutide Molecular Weight3 sources
• Retatrutide Storage and Stability3 sources
• How the Incretin Field Got Here3 sources
• Retatrutide Chemical Identity: What Can Actually Be Verified3 sources
• Retatrutide Half-Life: Where It Comes From3 sources
• Who Develops Retatrutide?3 sources
• The History of Retatrutide4 sources
• Retatrutide: Spellings, Codes and What Each Finds3 sources
• What Is a Triple Agonist?3 sources
• Retatrutide Molecular Structure and Properties3 sources
• What Does "Reta" Mean?3 sources
• Retatrutide Structure and Sequence3 sources
• What Is the TRIUMPH Trial Programme?4 sources
• Retatrutide Clinical Trial Timeline: Phase 1 to TRIUMPH4 sources
• Is Retatrutide FDA Approved? Regulatory Status Explained4 sources

Open research questions

• Is retatrutide the same molecule as LY3437943?
• What is the correct spelling: retatrutide or retatrutid?
• Is retatrutide a GLP-1 drug?
• Which company makes retatrutide?
• When will retatrutide be FDA approved?
• Is retatrutide legal in the UK?

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.

Handling checklist

• Store lyophilised vials at −20 °C; protect from light and humidity
• Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
• Once reconstituted, store at 2–8 °C and use within 28 days
• Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
• Do not administer to humans or animals. Research use only

Research applications

• In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
• Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
• Analytical-method development: HPLC retention profiling and LC-MS confirmation
• Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
• Reference material for teaching incretin pharmacology in university-level courses

Common mistakes

Confusing retatrutide with tirzepatide in supplier catalogues

Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

Using tap or filtered water for reconstitution

Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.

Storing reconstituted solution at room temperature

Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.